China Resources Double-Crane Unit Wins Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets
China Resources Double-Crane Pharmaceutical (600062) announced on September 14, 2026, that its wholly owned subsidiary China Resources Saike Pharmaceutical Co. , Ltd. has received a drug registration certificate from the National Medical Products Administration for ezetimibe and atorvastatin calcium tablets.
The certificate covers ezetimibe and atorvastatin calcium tablets (I) and ezetimibe and atorvastatin calcium tablets (II).
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 30/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.